Physician profile
Robert Glorioso
NPI 1306847348
$1,637.11
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $275 · 2021: $398 · 2022: $282 · 2023: $216 · 2024: $64.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $470.74 | 2019-2024 | |
| Novo Nordisk INC | $191.99 | 2019-2022 | |
| Abbvie INC. | $147.54 | 2021-2023 | |
| Abbott Laboratories | $119.74 | 2019-2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $105.46 | 2019-2022 | |
| Lilly USA, LLC | $78.09 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $70.37 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $46.50 | 2021 | |
| Genentech USA, INC. | $42.39 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.95 | 2019 | |
| Supernus Pharmaceuticals, INC. | $41.75 | 2023 | Qelbree |
| Lundbeck LLC | $33.16 | 2020-2021 | |
| Sanofi Pasteur INC. | $30.77 | 2019 | |
| Allergan, INC. | $29.91 | 2019-2020 | |
| Almatica Pharma LLC | $27.09 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.23 | 2019-2020 | |
| Dexcom, INC. | $19.73 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.91 | 2023 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2019 | |
| Eisai INC. | $17.03 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.83 | 2021 | |
| Merck Sharp & Dohme LLC | $16.63 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.17 | 2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Glorioso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.